Opposite Modulatory Effects of Selective and Non-Selective Cyclooxygenase Inhibition on Cardiovascular and Autonomic Consequences of Cyclosporine in Female Rats

Basic and Clinical Pharmacology and Toxicology

Volumn 120, Issue 6, 2017, Pages 571-581

  Ibrahim, Karim S ^a   El Yazbi, Ahmed F ^a   El Gowelli, Hanan M ^a   El Mas, Mahmoud M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLOSPORIN; DICLOFENAC; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; TAU PROTEIN; CYCLOSPORINE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME INHIBITION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART RATE VARIABILITY; HEMODYNAMICS; HYPERTENSION; NONHUMAN; PARASYMPATHETIC TONE; PRESSOR RESPONSE; PRIORITY JOURNAL; PULSE PRESSURE; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; AUTONOMIC NERVOUS SYSTEM; DRUG EFFECTS; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CELECOXIB; CYCLOOXYGENASE INHIBITORS; CYCLOSPORINE; DICLOFENAC; FEMALE; HEART RATE; HEMODYNAMICS; PYRAZOLES; RATS; RATS, WISTAR;

EID: 85014734111     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12754     Document Type: Article

References (59)

1. Cauduro RL, Costa C, Lhulier F, Garcia RG, Cabral RD, Gonçalves LFS et al. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 2005;19:470–4.
2. Nasser SA, Elmallah AI, Sabra R, Khedr MM, El-Din MMM, El-Mas MM. Blockade of endothelin ET(A), but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions. Eur J Pharmacol 2014;727:52–9.
3. Hardy G, Stanke-Labesque F, Deveaux G, Devillier P, Sessa C, Bessard G. Cyclosporine A and cremophor EL induce contractions of human saphenous vein: involvement of thromboxane A2 receptor-dependent pathway. J Cardiovasc Pharmacol 2000;36:693–8.
4. Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens 2000;13:999–1004.
5. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003;42:754–60.
6. El-Mas MM, Mohy El-din MM, Helmy MM, Omar AG. Redox imbalances incite the hypertensive, baroreflex, and autonomic effects of cyclosporine in rats. Eur J Pharmacol 2012;694:82–8.
7. Oriji GK, Tate JE, Keiser HR. Endothelin-induced prostacyclin production in rat aortic rings is mediated by protein kinase C. Prostaglandins Leukot Essent Fatty Acids 1996;55:309–13.
8. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807–18.
9. Praveen Rao PN, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81–110.
10. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
11. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep 2012;14:304–9.
12. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual. Lancet 2013;6736:1–11.
13. Yarishkin OV, Hwang EM, Kim D, Yoo JC, Kang SS, Kim DR et al. Diclofenac, a non-steroidal anti-inflammatory drug, inhibits L-type Ca channels in neonatal rat ventricular cardiomyocytes. Korean J Physiol Pharmacol 2009;13:437–42.
14. Feng G-S, Ma J-L, Wong BC, Zhang L, Liu W-D, Pan K-F et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol 2008;14:4535–9.
15. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–80. doi:10.1097/01.AOG.0000166692.14982.d1.
16. Cavalcante EGN, Aikawa NE, Lozano RG, Lotito APN, Jesus AA, Silva CA. Chronic polyarthritis as the first manifestation of juvenile systemic lupus erythematosus patients. Lupus 2011;20:960–4.
17. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26. doi:10.1136/ard.2011.150995
18. Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992;93:396–402.
19. Kovarik JM, Mueller EA, Gerbeau C, Tarral A, Francheteau P, Guerret M. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol 1997;37:336–43.
20. El-Mas MM, Helmy MW, Ali RM, El-Gowelli HM. Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling. Toxicol Appl Pharmacol 2015;284:1–7.
21. Helmy MW, El-Gowelli HM, Ali RM, El-Mas MM. Endothelin ETA receptor/lipid peroxides/COX-2/TGF-β1 signalling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats. Br J Pharmacol 2015;172:4291–302.
22. El-Gowelli HM, Helmy MW, Ali RM, El-Mas MM. Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ETB receptor cascade. Toxicol Appl Pharmacol 2014;275:88–95.
23. Hao C-M, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008;70:357–77.
24. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001;281:F1–11.
25. Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010;190:693–706.
26. El-Mas MM, Abdel-Rahman AA. Contrasting effects of urethane, ketamine, and thiopental anesthesia on ethanol-clonidine hemodynamic interaction. Alcohol Clin Exp Res 1997;21:19–27.
27. El-Mas MM, Abdel-Rahman AA. Role of cardiac output in ethanol-evoked attenuation of centrally mediated hypotension in conscious rats. Hypertension 1997;30:288–94.
28. El-Mas MM, Abdel-Rahman AA. Ethanol counteraction of I1-imidazoline but not alpha-2 adrenergic receptor-mediated reduction in vascular resistance in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 1999;288:455–62.
29. Omar AG, El-Mas MM. Time-domain evaluation of cyclosporine interaction with hemodynamic variability in rats. Cardiovasc Drugs Ther 2004;18:461–8.
30. El-Mas MM, Abdel-Rahman AA. Longitudinal studies on the effect of hypertension on circadian hemodynamic and autonomic rhythms in telemetered rats. Life Sci 2005;76:901–15.
31. Stein PK, Bosner MS, Kleiger RE, Conger BM. Heart rate variability: a measure of cardiac autonomic tone. Am Heart J 1994;127:1376–81.
32. El-Mas MM, Abdel-Rahman AA. Intermittent clonidine regimen abolishes tolerance to its antihypertensive effect: a spectral study. J Cardiovasc Pharmacol 2007;49:174–81.
33. Sehgal R, Kumar VL. Calotropis procera latex-induced inflammatory hyperalgesia–effect of antiinflammatory drugs. Mediators Inflamm 2005;2005:216–20.
34. Zhu CZ, Bannon AW, Joshi SK. Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. Eur J Pain 2015;19:1527–36.
35. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016;7:27–31.
36. Matsubara H, Takaki M, Yasuhara S, Araki J, Suga H. Logistic time constant of isovolumic relaxation pressure-time curve in the canine left ventricle. Better alternative to exponential time constant. Circulation 1995;92:2318–26.
37. Peng-Lin Y, Yue-Chun L. Pulse pressure index (pulse pressure/systolic pressure) may be better than pulse pressure for assessment of cardiovascular outcomes. Med Hypotheses 2009;72:729–31.
38. Shaltout HA, Abdel-Rahman AA. Cyclosporine induces progressive attenuation of baroreceptor heart rate response and cumulative pressor response in conscious unrestrained rats. J Pharmacol Exp Ther 2003;305:966–73.
39. Gardiner SM, March JE, Kemp PA, Fallgren B, Bennett T. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol 2004;141:634–43.
40. Schertel ER. Assessment of left-ventricular function. Thorac Cardiovasc Surg 1998;46(Suppl 2):248–54.
41. Klein IHHT, Abrahams AC, van Ede T, Oey PL, Ligtenberg G, Blankestijn PJ. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity. J Hypertens 2010;28:1928–34.
42. Huang C-H, Tsai M-S, Hsu C-Y, Su Y-J, Wang T-D, Chang W-T et al. Post-cardiac arrest myocardial dysfunction is improved with cyclosporine treatment at onset of resuscitation but not in the reperfusion phase. Resuscitation 2011;82(Suppl 2):S41–7.
43. El-Gowelli HM, El-Mas MM. Central modulation of cyclosporine-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol 2015;388:351–61.
44. Kleiger RE, Stein PK, Bigger JT. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005;10:88–101.
45. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709–11.
46. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–8. 2 p following 1528.
47. Cunha NV, de Abreu SB, Panis C, Grassiolli S, Guarnier FA, Cecchini R et al. Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats. Life Sci 2010;87:375–81.
48. Chuang H-C, Hsueh T-W, Chang C-C, Hwang J-S, Chuang K-J, Yan Y-H et al. Nickel-regulated heart rate variability: the roles of oxidative stress and inflammation. Toxicol Appl Pharmacol 2013;266:298–306.
49. Klein T, Eltze M, Grebe T, Hatzelmann A, Komhoff M. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 2007;75:390–7.
50. Grześk G, Szadujkis-Szadurska K, Matusiak G, Malinowski B, Gajdus M, Wiciński M et al. Influence of celecoxib on the vasodilating properties of human mesenteric arteries constricted with endothelin-1. Biomed Rep 2014;2:412–8.
51. LaPointe MC, Mendez M, Leung A, Tao Z, Yang X-P. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 2004;286:H1416–24.
52. Straino S, Salloum FN, Baldi A, Ockaili RA, Piro M, Das A et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 2007;50:571–7.
53. Veltman JD, Lambers MEH, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JGJV et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010;10:464.
54. Yokoyama T, Aramaki O, Takano S, Takayama T, Akiyama Y, Shibutani S et al. Cyclooxygenase-2 inhibitor induces operational tolerance to fully allogenic cardiac grafts. Transplant Proc 2002;34:1405–6.
55. Peeters P, Van Laecke S, Vanholder R. Acute kidney injury in solid organ transplant recipients. Acta Clin Belg 2007;62(Suppl. 2):389–92.
56. El-Mas MM, El-Gowilly SM, Gohar EY, Ghazal A-RM, Abdel-Rahman AA. Estrogen dependence of the renal vasodilatory effect of nicotine in rats: role of α7 nicotinic cholinergic receptor/eNOS signaling. Life Sci 2011;88:187–93.
57. El-Mas MM, Fouda MA, El-Gowilly SM, Saad EI. Central estrogenic pathways protect against the depressant action of acute nicotine on reflex tachycardia in female rats. Toxicol Appl Pharmacol 2012;258:410–7.
58. Goldman RK, Azar AS, Mulvaney JM, Hinojosa-Laborde C, Haywood JR, Brooks VL. Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids. Am J Physiol Regul Integr Comp Physiol 2009;296:R1419–26.
59. Agca R, Heslinga SC, van Halm VP, Nurmohamed MT. Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart 2016;102:790–5. doi:10.1136/heartjnl-2015-307838.